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BACKGROUND
Although several therapeutic agents have been evaluated for the treatment of coro-
navirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be 
efficacious.
METHODS
We conducted a double-blind, randomized, placebo-controlled trial of intravenous 
remdesivir in adults who were hospitalized with Covid-19 and had evidence of 
lower respiratory tract infection. Patients were randomly assigned to receive either 
remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 
9 additional days) or placebo for up to 10 days. The primary outcome was the time 
to recovery, defined by either discharge from the hospital or hospitalization for 
infection-control purposes only.
RESULTS
A total of 1062 patients underwent randomization (with 541 assigned to remdesi-
vir and 521 to placebo). Those who received remdesivir had a median recovery time 
of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% 
CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 
1.12 to 1.49; P<0.001, by a log-rank test). In an analysis that used a proportional-
odds model with an eight-category ordinal scale, the patients who received rem-
desivir were found to be more likely than those who received placebo to have 
clinical improvement at day 15 (odds ratio, 1.5; 95% CI, 1.2 to 1.9, after adjustment 
for actual disease severity). The Kaplan–Meier estimates of mortality were 6.7% 
with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 
15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). Serious 
adverse events were reported in 131 of the 532 patients who received remdesivir 
(24.6%) and in 163 of the 516 patients who received placebo (31.6%).
CONCLUSIONS
Our data show that remdesivir was superior to placebo in shortening the time to 
recovery in adults who were hospitalized with Covid-19 and had evidence of lower 
respiratory tract infection. (Funded by the National Institute of Allergy and Infec-
tious Diseases and others; ACTT-1 ClinicalTrials.gov number, NCT04280705.)
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A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 
2019 as the cause of a respiratory illness desig-
nated coronavirus disease 2019, or Covid-19.1 
Several therapeutic agents have been evaluated 
for the treatment of Covid-19, but no antiviral 
agents have yet been shown to be efficacious.2,3 
Since the publication of our preliminary report, 
dexamethasone has been shown to decrease mor-
tality (25.7% in the usual care group vs. 22.9% 
in the dexamethasone group; P<0.001), with the 
largest benefit seen among patients receiving 
invasive mechanical ventilation.4
Remdesivir (GS-5734), an inhibitor of the viral 
RNA-dependent, RNA polymerase with in vitro 
inhibitory activity against SARS-CoV-1 and the 
Middle East respiratory syndrome (MERS-CoV),5-8 
was identified early as a promising therapeutic 
candidate for Covid-19 because of its ability to 
inhibit SARS-CoV-2 in vitro.9 In addition, in non-
human primate studies, remdesivir initiated 12 
hours after inoculation with MERS-CoV10,11 re-
duced lung virus levels and lung damage.
To evaluate the clinical efficacy and safety of 
putative investigational therapeutic agents among 
hospitalized adults with laboratory-confirmed 
Covid-19, we designed an adaptive platform trial 
to rapidly conduct a series of phase 3, random-
ized, double-blind, placebo-controlled trials. 
Here, we describe the first stage of the Adaptive 
Covid-19 Treatment Trial (ACTT-1), in which we 
evaluated treatment with remdesivir as com-
pared with placebo. The results presented here 




Enrollment for ACTT-1 began on February 21, 
2020, and ended on April 19, 2020. There were 
60 trial sites and 13 subsites in the United States 
(45 sites), Denmark (8), the United Kingdom (5), 
Greece (4), Germany (3), Korea (2), Mexico (2), 
Spain (2), Japan (1), and Singapore (1). Eligible 
patients were randomly assigned in a 1:1 ratio to 
receive either remdesivir or placebo. Randomiza-
tion was stratified by study site and disease se-
verity at enrollment. Patients were considered to 
have severe disease if they required mechanical 
ventilation, if they required supplemental oxy-
gen, if the oxygen saturation as measured by 
pulse oximetry (Spo2) was 94% or lower while 
they were breathing ambient air, or if they had 
tachypnea (respiratory rate ≥24 breaths per min-
ute). Remdesivir was administered intravenously 
as a 200-mg loading dose on day 1, followed by 
a 100-mg maintenance dose administered daily 
on days 2 through 10 or until hospital discharge 
or death. A matching placebo was administered 
according to the same schedule and in the same 
volume as the active drug. A normal saline pla-
cebo was used at the European sites and at some 
non-European sites owing to a shortage of match-
ing placebo; for these sites, the remdesivir and 
placebo infusions were masked with an opaque 
bag and tubing covers to maintain blinding. All 
patients received supportive care according to 
the standard of care for the trial site hospital. 
If a hospital had a written policy or guideline for 
use of other treatments for Covid-19, patients 
could receive those treatments. In the absence of 
a written policy or guideline, other experimental 
treatment or off-label use of marketed medica-
tions intended as specific treatment for Covid-19 
were prohibited from day 1 through day 29 
(though such medications could have been used 
before enrollment in this trial).
The trial protocol was approved by the insti-
tutional review board at each site (or by a cen-
tralized institutional review board as applicable) 
and was overseen by an independent data and 
safety monitoring board. Written informed con-
sent (or consent by other institutional review 
board—approved process) was obtained from each 
patient or from the patient’s legally authorized 
representative if the patient was unable to pro-
vide consent. Full details of the trial design, con-
duct, oversight, and analyses can be found in the 
protocol and statistical analysis plan (available 
with the full text of this article at NEJM.org).
Procedures
Patients were assessed daily during their hospi-
talization, from day 1 through day 29. Patients’ 
clinical status was assessed on an eight-category 
ordinal scale (defined below) and the National 
Early Warning Score (which includes six physi-
ological measures; total scores range from 0 to 
20, with higher scores indicating greater clinical 
risk) were recorded each day.12,13 All serious ad-
verse events and grade 3 or 4 adverse events that 
represented an increase in severity from day 1 
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and any grade 2 or higher suspected drug-related 
hypersensitivity reactions were recorded. (See the 
full description of trial procedures in the Supple-
mentary Appendix, available at NEJM.org.)
Outcomes
The primary outcome was the time to recovery, 
defined as the first day, during the 28 days after 
enrollment, on which a patient met the criteria 
for category 1, 2, or 3 on the eight-category or-
dinal scale. The categories are as follows: 1, not 
hospitalized and no limitations of activities; 2, 
not hospitalized, with limitation of activities, 
home oxygen requirement, or both; 3, hospital-
ized, not requiring supplemental oxygen and no 
longer requiring ongoing medical care (used if 
hospitalization was extended for infection-con-
trol or other nonmedical reasons); 4, hospital-
ized, not requiring supplemental oxygen but re-
quiring ongoing medical care (related to Covid-19 
or to other medical conditions); 5, hospitalized, 
requiring any supplemental oxygen; 6, hospital-
ized, requiring noninvasive ventilation or use of 
high-flow oxygen devices; 7, hospitalized, receiv-
ing invasive mechanical ventilation or extracor-
poreal membrane oxygenation (ECMO); and 8, 
death.
The key secondary outcome was clinical sta-
tus at day 15, as assessed on the ordinal scale. 
Other secondary outcomes included the time to 
improvement of one category and of two catego-
ries from the baseline ordinal score; clinical 
status as assessed on the ordinal scale at days 3, 
5, 8, 11, 15, 22, and 29; mean change in status 
on the ordinal scale from day 1 to days 3, 5, 8, 
11, 15, 22, and 29; time to discharge or Na-
tional Early Warning Score of 2 or less (main-
tained for 24 hours), whichever occurred first; 
change in the National Early Warning Score 
from day 1 to days 3, 5, 8, 11, 15, 22, and 29; 
number of days with supplemental oxygen, with 
noninvasive ventilation or high-flow oxygen, and 
with invasive ventilation or ECMO up to day 29 
(if these were being used at baseline); the inci-
dence and duration of new oxygen use, of non-
invasive ventilation or high-flow oxygen, and of 
invasive ventilation or ECMO; number of days of 
hospitalization up to day 29; and mortality at 14 
and 28 days after enrollment. Secondary safety 
outcome measures included grade 3 and 4 ad-
verse events and serious adverse events that oc-
curred during the trial, discontinuation or tem-
porary suspension of infusions, and changes in 
assessed laboratory values over time.
Statistical Analysis
The primary analysis was a stratified log-rank 
test of time to recovery with remdesivir as com-
pared with placebo, with stratification by disease 
severity (the actual severity at baseline). (See the 
Supplementary Appendix for more information 
about the planned statistical analysis.) For time-
to-recovery and time-to-improvement analyses, 
data for patients who did not recover and data 
for patients who died were censored at day 29.
Prespecified subgroups in these analyses were 
defined according to sex, baseline disease sever-
ity (according to stratification criteria and on the 
basis of the ordinal scale), age (18 to 39 years, 
40 to 64 years, or ≥65 years), race, ethnic group, 
duration of symptoms before randomization 
(measured as ≤10 days or >10 days, in quartiles, 
and as the median), site location, and presence 
of coexisting conditions. (See the protocol for 
more information about the trial methods.) To 
assess the effect of disease severity on treatment 
benefit (recovery and mortality), post hoc analy-
ses evaluated interactions of efficacy with base-
line ordinal score (as a continuous variable).
The primary outcome was initially a com-
parison of clinical status at day 15 on the eight-
category ordinal scale. However, the primary 
outcome was changed to a comparison of time 
to recovery by day 29 in response to evolving 
information, external to the trial, indicating that 
Covid-19 may have a more protracted course 
than previously anticipated. The change was 
proposed on March 22, 2020 (after 72 patients 
had been enrolled), by trial statisticians who 
were unaware of treatment assignments and had 
no knowledge of outcome data. The amendment 
was finalized on April 2, 2020, and the initial 
primary outcome was retained as the key sec-
ondary outcome.
On April 27, 2020, the data and safety moni-
toring board reviewed efficacy results. Although 
this review was originally planned as an interim 
analysis, because of the rapid pace of enroll-
ment, the review occurred after completion of 
enrollment while follow-up was still ongoing. At 
the time of the data and safety monitoring board 
report, which was based on data cutoff date of 
April 22, 2020, a total of 482 recoveries (exceed-
ing the estimated number of recoveries needed 
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for the trial) and 81 deaths had been entered in 
the database. At that time, the data and safety 
monitoring board recommended that the pre-
liminary primary analysis report and mortality 
data from the closed safety report be provided to 
trial team members from the National Institute 
of Allergy and Infectious Diseases (NIAID). These 
results were subsequently made public. The treat-
ing physician could request to be made aware of 
the treatment assignment of patients who had 
not completed day 29 if clinically indicated (e.g., 
because of worsening clinical status), and pa-




Of the 1114 patients who were assessed for eli-
gibility, 1062 underwent randomization; 541 were 
assigned to the remdesivir group and 521 to the 
placebo group (intention-to-treat population) 
(Fig. 1); 159 (15.0%) were categorized as having 
mild-to-moderate disease, and 903 (85.0%) were 
in the severe disease stratum. Of those assigned 
to receive remdesivir, 531 patients (98.2%) re-
ceived the treatment as assigned. Fifty-two pa-
tients had remdesivir treatment discontinued 
before day 10 because of an adverse event or a 
serious adverse event other than death and 10 
withdrew consent. Of those assigned to receive 
placebo, 517 patients (99.2%) received placebo as 
assigned. Seventy patients discontinued placebo 
before day 10 because of an adverse event or a 
serious adverse event other than death and 14 
withdrew consent.
A total of 517 patients in the remdesivir group 
and 508 in the placebo group completed the 
trial through day 29, recovered, or died. Four-
teen patients who received remdesivir and 9 who 
received placebo terminated their participation 
in the trial before day 29. A total of 54 of the 
patients who were in the mild-to-moderate stra-
tum at randomization were subsequently deter-
mined to meet the criteria for severe disease, 
resulting in 105 patients in the mild-to-moderate 
disease stratum and 957 in the severe stratum. 
The as-treated population included 1048 patients 
who received the assigned treatment (532 in the 
remdesivir group, including one patient who had 
been randomly assigned to placebo and received 
remdesivir, and 516 in the placebo group).
The mean age of the patients was 58.9 years, 
and 64.4% were male (Table 1). On the basis of 
the evolving epidemiology of Covid-19 during the 
trial, 79.8% of patients were enrolled at sites in 
North America, 15.3% in Europe, and 4.9% in 
Asia (Table S1 in the Supplementary Appendix). 
Overall, 53.3% of the patients were White, 21.3% 
were Black, 12.7% were Asian, and 12.7% were 
designated as other or not reported; 250 (23.5%) 
were Hispanic or Latino. Most patients had ei-
ther one (25.9%) or two or more (54.5%) of the 
prespecified coexisting conditions at enrollment, 
most commonly hypertension (50.2%), obesity 
(44.8%), and type 2 diabetes mellitus (30.3%).
The median number of days between symp-
tom onset and randomization was 9 (interquar-
tile range, 6 to 12) (Table S2). A total of 957 
patients (90.1%) had severe disease at enroll-
ment; 285 patients (26.8%) met category 7 crite-
ria on the ordinal scale, 193 (18.2%) category 6, 
435 (41.0%) category 5, and 138 (13.0%) catego-
ry 4. Eleven patients (1.0%) had missing ordinal 
scale data at enrollment; all these patients dis-
continued the study before treatment. During the 
study, 373 patients (35.6% of the 1048 patients 
in the as-treated population) received hydroxy-
chloroquine and 241 (23.0%) received a gluco-
corticoid (Table S3).
Primary Outcome
Patients in the remdesivir group had a shorter 
time to recovery than patients in the placebo 
group (median, 10 days, as compared with 15 
days; rate ratio for recovery, 1.29; 95% confi-
dence interval [CI], 1.12 to 1.49; P<0.001) (Fig. 2 
and Table 2). In the severe disease stratum (957 
patients) the median time to recovery was 11 
days, as compared with 18 days (rate ratio for 
recovery, 1.31; 95% CI, 1.12 to 1.52) (Table S4). 
The rate ratio for recovery was largest among 
patients with a baseline ordinal score of 5 (rate 
ratio for recovery, 1.45; 95% CI, 1.18 to 1.79); 
among patients with a baseline score of 4 and 
those with a baseline score of 6, the rate ratio 
estimates for recovery were 1.29 (95% CI, 0.91 to 
1.83) and 1.09 (95% CI, 0.76 to 1.57), respec-
tively. For those receiving mechanical ventilation 
or ECMO at enrollment (baseline ordinal score 
of 7), the rate ratio for recovery was 0.98 (95% 
CI, 0.70 to 1.36). Information on interactions of 
treatment with baseline ordinal score as a con-
tinuous variable is provided in Table S11. An 
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Figure 1. Enrollment and Randomization.
1062 Underwent randomization
1114 Patients were assessed for eligibility
52 Were excluded
28 Were ineligible owing to meeting
exclusion criteria or not meeting
inclusion criteria
24 Were eligible, but were not enrolled
541 Were assigned to receive remdesivir
531 Received remdesivir
10 Did not receive remdesivir
521 Were assigned to receive placebo
517 Received placebo
4 Did not receive placebo
10 Were excluded owing to
not receiving at least one
infusion
1 Was randomized to rem-
desivir but received placebo
4 Were excluded owing to
not receiving at least one
infusion
1 Was randomized to placebo
but received remdesivir
208 Received all 10 doses
323 Received <10 doses
223 Recovered
15 Died
18 Missed doses intermittently
52 Discontinued owing to adverse
event or severe adverse event,
other than death
4 Were withdrawn by investigator
6 Withdrew
4 Withdrew and transitioned to
comfort care
1 Was transferred to another
hospital
226 Received all 10 doses
291 Received <10 doses
158 Recovered
19 Died
26 Missed doses intermittently
70 Discontinued owing to adverse
event or severe adverse event,
other than death
1 Was withdrawn by investigator
8 Withdrew 
6 Withdrew and transitioned to
comfort care
1 Was transferred to another
hospital
1 Became ineligible after enrollment
1 Had protocol deviation
517 Completed  the study (includes death
and recovery)
14 Terminated early (excludes death
and recovery)
4 Had adverse event or severe
adverse event, other than death
6 Withdrew
3 Withdrew and transitioned to
comfort care
1 Was transferred to another
hospital
508 Completed  the study (includes death
and recovery)
9 Terminated early (excludes death
and recovery)
1 Was withdrawn by investigator
5 Withdrew
2 Withdrew and transitioned to
comfort care
1 Was transferred to another
hospital
541 Were included in the intention-to-
treat population
521 Were included in the intention-to-
treat population
532 Were included in the as-treated
population
516 Were included in the as-treated
population
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analysis adjusting for baseline ordinal score as a 
covariate was conducted to evaluate the overall 
effect (of the percentage of patients in each or-
dinal score category at baseline) on the primary 
outcome. This adjusted analysis produced a simi-
lar treatment-effect estimate (rate ratio for re-
covery, 1.26; 95% CI, 1.09 to 1.46). Patients who 
underwent randomization during the first 10 days 
after the onset of symptoms had a rate ratio for 
recovery of 1.37 (95% CI, 1.14 to 1.64), whereas 
patients who underwent randomization more 





 (N = 541)
Placebo 
(N = 521)
Age — yr 58.9±15.0 58.6±14.6 59.2±15.4
Male sex — no. (%) 684 (64.4) 352 (65.1) 332 (63.7)
Race or ethnic group — no. (%)†
American Indian or Alaska Native  7 (0.7)  4 (0.7)  3 (0.6)
Asian 135 (12.7)  79 (14.6)  56 (10.7)
Black or African American 226 (21.3) 109 (20.1) 117 (22.5)
White 566 (53.3) 279 (51.6) 287 (55.1)
Hispanic or Latino — no. (%) 250 (23.5) 134 (24.8) 116 (22.3)
Median time (IQR) from symptom onset to randomization — days‡ 9 (6–12) 9 (6–12) 9 (7–13)
No. of coexisting conditions — no. /total no. (%)‡
None 194/1048 (18.5) 97/531 (18.3) 97/517 (18.8)
One 275/1048 (26.2) 138/531 (26.0) 137/517 (26.5)
Two or more 579/1048 (55.2) 296/531 (55.7) 283/517 (54.7)
Coexisting conditions — no./total no. (%)
Type 2 diabetes 322/1051 (30.6) 164/532 (30.8) 158/519 (30.4)
Hypertension 533/1051 (50.7) 269/532 (50.6) 264/519 (50.9)
Obesity 476/1049 (45.4) 242/531 (45.6) 234/518 (45.2)
Score on ordinal scale — no. (%)
4. Hospitalized, not requiring supplemental oxygen, requiring 
 ongoing medical care (Covid-19–related or otherwise)
138 (13.0)  75 (13.9)  63 (12.1)
5. Hospitalized, requiring supplemental oxygen 435 (41.0) 232 (42.9) 203 (39.0)
6. Hospitalized, receiving noninvasive ventilation or high-flow 
 oxygen devices
193 (18.2)  95 (17.6)  98 (18.8)
7. Hospitalized, receiving invasive mechanical ventilation or ECMO 285 (26.8) 131 (24.2) 154 (29.6)
Baseline score missing 11 (1.0)  8 (1.5)  3 (0.6)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. IQR denotes interquartile range, and ECMO extra-
corporeal membrane oxygenation. The full table of baseline characteristics is available in the Supplementary Appendix.
†  Race and ethnic group were reported by the patients. The number of patients in other races and ethnic groups are listed in Table S1 in the 
Supplementary Appendix.
‡  Data on symptom onset were missing for 3 patients; data on coexisting conditions were missing for 11 patients and were incomplete for  
3 patients.
Figure 2 (facing page). Kaplan–Meier Estimates  
of Cumulative Recoveries.
Cumulative recovery estimates are shown in the overall 
population (Panel A), in patients with a baseline score 
of 4 on the ordinal scale (not receiving oxygen; Panel B), 
in those with a baseline score of 5 (receiving oxygen; 
Panel C), in those with a baseline score of 6 (receiving 
high-flow oxygen or noninvasive mechanical ventilation; 
Panel D), and in those with a baseline score of 7 (receiv-
ing mechanical ventilation or extracorporeal membrane 
oxygenation [ECMO]; Panel E).





























































































































































































































































































E Patients Receiving Mechanical Ventilation or ECMO
D Patients Receiving High-Flow Oxygen or Noninvasive Mechanical
Ventilation 
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than 10 days after the onset of symptoms had a 
rate ratio for recovery of 1.20 (95% CI, 0.94 to 
1.52) (Fig. 3). The benefit of remdesivir was 
larger when given earlier in the illness, though 
the benefit persisted in most analyses of dura-
tion of symptoms (Table S6). Sensitivity analyses 
in which data were censored at earliest reported 
use of glucocorticoids or hydroxychloroquine still 
showed efficacy of remdesivir (9.0 days to recov-
ery with remdesivir vs. 14.0 days to recovery with 
placebo; rate ratio, 1.28; 95% CI, 1.09 to 1.50, 
and 10.0 vs. 16.0 days to recovery; rate ratio, 1.32; 
95% CI, 1.11 to 1.58, respectively) (Table S8).
Key Secondary Outcome
The odds of improvement in the ordinal scale 
score were higher in the remdesivir group, as 
determined by a proportional odds model at the 
day 15 visit, than in the placebo group (odds ratio 
for improvement, 1.5; 95% CI, 1.2 to 1.9, adjusted 
for disease severity) (Table 2 and Fig. S7).
Mortality
Kaplan–Meier estimates of mortality by day 15 
were 6.7% in the remdesivir group and 11.9% in 
the placebo group (hazard ratio, 0.55; 95% CI, 
0.36 to 0.83); the estimates by day 29 were 11.4% 
and 15.2% in two groups, respectively (hazard 
ratio, 0.73; 95% CI, 0.52 to 1.03). The between-
group differences in mortality varied consider-
ably according to baseline severity (Table 2), with 
the largest difference seen among patients with 
a baseline ordinal score of 5 (hazard ratio, 0.30; 
95% CI, 0.14 to 0.64). Information on interac-
tions of treatment with baseline ordinal score 
with respect to mortality is provided in Table S11.
Additional Secondary Outcomes
Patients in the remdesivir group had a shorter 
time to improvement of one or of two categories 
on the ordinal scale from baseline than patients 
in the placebo group (one-category improvement: 
median, 7 vs. 9 days; rate ratio for recovery, 1.23; 
95% CI, 1.08 to 1.41; two-category improvement: 
median, 11 vs. 14 days; rate ratio, 1.29; 95% CI, 
1.12 to 1.48) (Table 3). Patients in the remdesivir 
group had a shorter time to discharge or to a 
National Early Warning Score of 2 or lower than 
those in the placebo group (median, 8 days vs. 
12 days; hazard ratio, 1.27; 95% CI, 1.10 to 1.46). 
The initial length of hospital stay was shorter in 
the remdesivir group than in the placebo group 
(median, 12 days vs. 17 days); 5% of patients in 
the remdesivir group were readmitted to the hos-
pital, as compared with 3% in the placebo group.
Among the 913 patients receiving oxygen at 
enrollment, those in the remdesivir group con-
tinued to receive oxygen for fewer days than 
patients in the placebo group (median, 13 days 
vs. 21 days), and the incidence of new oxygen 
use among patients who were not receiving oxy-
gen at enrollment was lower in the remdesivir 
group than in the placebo group (incidence, 36% 
[95% CI, 26 to 47] vs. 44% [95% CI, 33 to 57]). 
For the 193 patients receiving noninvasive venti-
lation or high-flow oxygen at enrollment, the 
median duration of use of these interventions 
was 6 days in both the remdesivir and placebo 
groups. Among the 573 patients who were not 
receiving noninvasive ventilation, high-flow oxy-
gen, invasive ventilation, or ECMO at baseline, 
the incidence of new noninvasive ventilation or 
high-flow oxygen use was lower in the remdesi-
vir group than in the placebo group (17% [95% 
CI, 13 to 22] vs. 24% [95% CI, 19 to 30]). Among 
the 285 patients who were receiving mechanical 
ventilation or ECMO at enrollment, patients in 
the remdesivir group received these interven-
tions for fewer subsequent days than those in 
the placebo group (median, 17 days vs. 20 days), 
and the incidence of new mechanical ventilation 
or ECMO use among the 766 patients who were 
not receiving these interventions at enrollment 
was lower in the remdesivir group than in the 
placebo group (13% [95% CI, 10 to 17] vs. 23% 
[95% CI, 19 to 27]) (Table 3).
Safety Outcomes
In the as-treated population, serious adverse 
events occurred in 131 of 532 patients (24.6%) in 
the remdesivir group and in 163 of 516 patients 
(31.6%) in the placebo group (Table S17). There 
were 47 serious respiratory failure adverse events 
in the remdesivir group (8.8% of patients), in-
cluding acute respiratory failure and the need for 
endotracheal intubation, and 80 in the placebo 
group (15.5% of patients) (Table S19). No deaths 
were considered by the investigators to be relat-
ed to treatment assignment.
Grade 3 or 4 adverse events occurred on or 
before day 29 in 273 patients (51.3%) in the rem-
desivir group and in 295 (57.2%) in the placebo 
group (Table S18); 41 events were judged by the 
investigators to be related to remdesivir and 47 
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events to placebo (Table S17). The most common 
nonserious adverse events occurring in at least 5% 
of all patients included decreased glomerular fil-
tration rate, decreased hemoglobin level, decreased 
lymphocyte count, respiratory failure, anemia, 
pyrexia, hyperglycemia, increased blood creati-
nine level, and increased blood glucose level (Ta-
ble S20). The incidence of these adverse events 
was generally similar in the remdesivir and pla-
cebo groups.
Crossover
After the data and safety monitoring board rec-
ommended that the preliminary primary analy-
sis report be provided to the sponsor, data on a 
total of 51 patients (4.8% of the total study en-
rollment) — 16 (3.0%) in the remdesivir group 
and 35 (6.7%) in the placebo group — were un-
blinded; 26 (74.3%) of those in the placebo 
group whose data were unblinded were given 
remdesivir. Sensitivity analyses evaluating the 
unblinding (patients whose treatment assign-
ments were unblinded had their data censored at 
the time of unblinding) and crossover (patients 
in the placebo group treated with remdesivir had 
their data censored at the initiation of remdesi-
vir treatment) produced results similar to those 
of the primary analysis (Table S9).
Figure 3. Time to Recovery According to Subgroup.
The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. 
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Discussion
This double-blind, randomized, placebo-con-
trolled trial identified an antiviral therapy as 
beneficial in the treatment of Covid-19. Our 
overall findings were consistent with the find-
ings of the preliminary report: a 10-day course 
of remdesivir was superior to placebo in the 
treatment of hospitalized patients with Covid-19. 
Patients who received remdesivir had a shorter 
time to recovery (the primary end point) than 
those who received placebo (median, 10 days vs. 
15 days; rate ratio for recovery, 1.29 [95% CI, 
1.12 to 1.49]) and were more likely to have im-







Median time to clinical improvement (95% CI) — days
Improvement of one category on ordinal scale 7.0 (6.0 to 8.0) 9.0 (8.0 to 11.0) 1.23 (1.08 to 1.41)
Improvement of two categories on ordinal scale 11.0 (10.0 to 13.0) 14.0 (13.0 to 15.0) 1.29 (1.12 to 1.48)
Discharge or National Early Warning Score ≤2 for 24 hr* 8.0 (7.0 to 9.0) 12.0 (10.0 to 15.0) 1.27 (1.10 to 1.46)
Difference (95% CI)
Hospitalization
Median duration of initial hospitalization (IQR) — days† 12 (6 to 28) 17 (8 to 28) −5.0 (−7.7 to −2.3)
Median duration of initial hospitalization among those who did 
not die (IQR) — days
10 (5 to 21) 14 (7 to 27) −4.0 (−6.0 to −2.0)
Patients rehospitalized — % (95% CI) 5 (3 to 7) 3 (2 to 5) 2 percentage points 
(0 to 4)
Oxygen
Median days receiving oxygen if receiving oxygen at baseline (IQR) 13 (5 to 28) 21 (8 to 28) −8.0 (−11.8 to −4.2)
New use of oxygen
No. of patients/total no. 27/75 28/63
Percent of patients (95% CI) 36 (26 to 47) 44 (33 to 57) −8 (−24 to 8)
Median days receiving oxygen (IQR) 4 (2 to 12) 5.5 (1 to 15) −1.0 (−7.6 to 5.6)
Noninvasive ventilation or high-flow oxygen
Median days of noninvasive ventilation or high-flow oxygen use 
during study if receiving these interventions at baseline 
(IQR)
6 (3 to 18) 6 (3 to 16) 0 (−2.6 to 2.6)
New use of new noninvasive ventilation or high-flow oxygen use 
during the study
No. of patients/total no. 52/307 64/266
Percent of patients (95% CI) 17 (13 to 22) 24 (19 to 30) −7 (−14 to −1)
Median days of use during the study (IQR) 3 (1 to 10.5) 4 (2 to 23.5) −1.0 (−4.0 to 2.0)
Mechanical ventilation or ECMO
Median days of mechanical ventilation or ECMO during study  
if receiving these interventions at baseline (IQR)
17 (9 to 28) 20 (8 to 28) −3.0 (−9.3 to 3.3)
New use of mechanical ventilation or ECMO during study
No. of patients/total no. 52/402 82/364
Percent of patients (95% CI) 13 (10 to 17) 23 (19 to 27) −10 (−15 to −4)
Median days of use during the study (IQR) 21.5 (9 to 28) 23 (12 to 28) 1.0 (−6.0 to 8.0)
*  The National Early Warning Score includes six physiological measures; total scores range from 0 to 20, with higher scores indicating greater 
clinical risk.
†  The duration of initial hospitalization for patients who died was imputed as 28 days.
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provement in the ordinal scale score at day 15 
(key secondary end point; odds ratio, 1.5; 95% 
CI, 1.2 to 1.9). Additional secondary end points 
supporting these findings include remdesivir 
treatment resulting in a shorter time to improve-
ment of one and of two ordinal scale categories, 
a shorter time to discharge or to a sustained 
National Early Warning Score of 2 or lower, and 
a shorter length of initial hospital stay (median, 
12 days vs. 17 days). All-cause mortality was 
11.4% with remdesivir and 15.2% with placebo 
(hazard ratio, 0.73; 95% CI, 0.52 to 1.03).
Our data also suggest that treatment with 
remdesivir may have prevented the progression 
to more severe respiratory disease, as shown by 
the lower proportion of serious adverse events 
due to respiratory failure among patients in the 
remdesivir group, as well as a lower incidence of 
new oxygen use among patients who were not 
receiving oxygen at enrollment and a lower pro-
portion of patients needing higher levels of re-
spiratory support during the study. Treatment 
with remdesivir was associated with fewer days 
of subsequent oxygen use for patients receiving 
oxygen at enrollment and shorter subsequent 
duration of mechanical ventilation or ECMO for 
those receiving these interventions at enrollment. 
Cumulatively, these findings suggest that treat-
ment with remdesivir may not only reduce the 
disease burden but may also decrease the use 
of scarce health care resources during this pan-
demic. The benefit in recovery persisted when 
adjustment was made for glucocorticoid use, 
which suggests that the benefit of dexametha-
sone as shown in the Randomized Evaluation of 
Covid-19 Therapy (RECOVERY) trial4 may be ad-
ditive to that of remdesivir.
The benefit of remdesivir was most apparent 
in patients with a baseline ordinal score of 5 
(receiving low-flow oxygen). Some of this differ-
ence may be due to the larger sample size in this 
category since confidence intervals for baseline 
ordinal scores of 4 (not receiving oxygen), 6 (re-
ceiving high-flow oxygen), and 7 (receiving ECMO 
or mechanical ventilation) were wide. However, 
the interaction tests suggest greater benefit 
(with respect to recovery and mortality) in lower 
ordinal score categories. This should not be in-
terpreted as conclusively showing a lack of effi-
cacy in higher ordinal score categories. The 
median recovery time for patients in category 7 
could not be estimated, which suggests that the 
follow-up time may have been too short to 
evaluate that subgroup.
The findings in our trial should be compared 
with those observed in other randomized trials 
of remdesivir. Wang et al. enrolled 237 patients 
(158 assigned to remdesivir and 79 to placebo) 
in China early in the pandemic and showed a 
shorter time to improvement (a two-point im-
provement) with remdesivir: 21.0 days (95% CI, 
13.0 to 28.0) in the remdesivir group and 23.0 
days (95% CI, 15.0 to 28.0) in the placebo group 
(hazard ratio for clinical improvement, 1.23; 
95% CI, 0.87 to 1.75).14 That trial did not com-
plete full enrollment owing to local control of 
the outbreak, had lower power than ACTT-1 ow-
ing to the smaller sample size and a 2:1 random-
ization, and was unable to demonstrate any 
statistically significant clinical benefits of rem-
desivir. In the recently published, open-label, 
randomized study of remdesivir in hospitalized 
patients with moderate-severity Covid-19 (83% 
were not receiving oxygen at baseline), patients 
who received remdesivir for 5 days had higher 
odds of clinical improvement than those receiv-
ing standard care (odds ratio, 1.65; 95% CI, 1.09 
to 2.48; P = 0.02). This benefit was not seen with 
the 10-day course (P = 0.18).15 We believe that 
these other studies support our findings regard-
ing the efficacy of remdesivir; however, our 
study was larger, blinded, and fully enrolled.
The primary outcome of the current trial was 
changed early in the trial, from a comparison of 
the eight-category ordinal scale scores on day 15 
to a comparison of time to recovery up to day 29. 
Little was known about the natural clinical 
course of Covid-19 when the trial was designed 
in February 2020. Emerging data suggested that 
Covid-19 had a more protracted course than was 
previously known, which aroused concern that a 
difference in outcome after day 15 would have 
been missed by a single assessment at day 15. 
The amendment was proposed on March 22, 
2020, by trial statisticians who were unaware of 
treatment assignment and had no knowledge of 
outcome data; when this change was proposed 
72 patients had been enrolled. Although chang-
es in the primary outcome are not common in 
trials for diseases that are well understood, it is 
recognized that in some trials, such as those 
involving poorly understood diseases, circum-
stances may require a change in the way an 
outcome is assessed or may necessitate a differ-
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ent outcome.16 The original primary outcome 
became the key secondary end point. In the end, 
findings for both primary and key secondary 
end points were significantly different between 
the remdesivir and placebo groups.
Numerous challenges were encountered dur-
ing this trial. The trial was implemented during 
a time of restricted travel, and hospitals restrict-
ed the entrance of nonessential personnel. Train-
ing, site initiation visits, and monitoring visits 
often were performed remotely. Research staff 
were often assigned other clinical duties, and 
staff illnesses strained research resources. Many 
sites did not have adequate supplies of personal 
protective equipment and trial-related supplies, 
such as swabs. However, research teams were 
motivated to find creative solutions to overcome 
these challenges. Throughout the trial, we were 
able to enroll a diverse population, similar to the 
population that was being infected with SARS-
CoV-2 during that period.
Given the preliminary results about remdesi-
vir, the Food and Drug Administration issued 
an Emergency Use Authorization on May 1, 2020 
(modified on August 28, 2020), to permit the use 
of remdesivir for treatment in adults and chil-
dren hospitalized with suspected or laboratory-
confirmed Covid-19. Remdesivir has also received 
full or conditional approval in several other 
countries since that time. However, given high 
mortality despite the use of remdesivir, it is clear 
that treatment with an antiviral drug alone is not 
likely to be sufficient for all patients. Current 
strategies are evaluating remdesivir in combina-
tion with modifiers of the immune response 
(e.g., the Janus kinase [JAK] inhibitor baricitinib 
in ACTT-2, and interferon beta-1a in ACTT-3). A 
variety of therapeutic approaches including novel 
antivirals, modifiers of the immune response 
or other intrinsic pathways, and combination 
approaches are needed to continue to improve 
outcomes in patients with Covid-19.
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